VNPEPS
Class context · 2 Nov 2026

The Wegovy pill: oral semaglutide in development

Novo Nordisk is testing oral semaglutide at weight-loss doses — a development of the Rybelsus (SNAC absorber) technology.

The facts

The technology

The same SNAC platform as Rybelsus, at obesity-program doses.

Status

Clinical development; no obesity registration yet.

Context

Confirms the trend: pharma solves the oral barrier point-by-point — the research peptide market stays injectable.

5/5 from 19 published reviews with photos (12 Nov 2026). All reviews with photos.

Is this about medicines or research materials?

The page describes registered medicines/developments in a research context. We sell research materials only — not medicines.

Do you have any of these?

No branded medicines. Research-class analogues are in the dated index.

Research-class materials

🇻🇳 Dated index of 46 compounds · Telegram @vietpep · written before payment.